To fund its attempts to carry MDMA therapy to industry, MAPS General public Advantage Corporation (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but did not settle for investment in return for fairness and could not secure the $70 million required to go forward — has morphed into the for-income Lykos Therapeutics.Wha… Read More